CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	Page 1,line1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	Page 1-2,line19-50
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	Page 3-4,line 52-91
	2b	Specific objectives or hypotheses	Page 4-5,line 92-102
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Page 5-6,line 104-127
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	--
Participants	4a	Eligibility criteria for participants	Page 5,line 105-109
	4b	Settings and locations where the data were collected	Page 5,line 117-119
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Page 14,line 302-304
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	--
	6b	Any changes to trial outcomes after the trial commenced, with reasons	--
Sample size	7a	How sample size was determined	Page 6,line 119-127
	7b	When applicable, explanation of any interim analyses and stopping guidelines	--
Randomisation:			--
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	--

Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	--
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	--
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	--
	11b	If relevant, description of the similarity of interventions	--
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	Page 14,line 302-304
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	Page 14,line 302-304
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	--
	13b	For each group, losses and exclusions after randomisation, together with reasons	--
Recruitment	14a	Dates defining the periods of recruitment and follow-up	Page 5,line 113-116
	14b	Why the trial ended or was stopped	--
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	See supplement-1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	--
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Page 14-20,line 308-431
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	--
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	--
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	--
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	--
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Page 20-

			22,line 432-476
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Page 14-20,line 308-431
Other information			
Registration	23	Registration number and name of trial registry	--
Protocol	24	Where the full trial protocol can be accessed, if available	--
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Page 22,line 487-488

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

Article information: http://dx.doi.org/10.21037/tcr-20-1132

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	commercial reagents have provided supplier name (see page 13, line 289-298)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Cell lines have Provided species information, strain and catalog number(see page 7, line 147-151)	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	--	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	--	
Animal observed in or captured from the field: Provide species, sex and age where possible	--	
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	--	

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	--	
Microbes: provide species and strain, unique accession number if available, and source	--	

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethics committee of the Yunnan Cancer Hospital (see page 23, line 497).	
Provide statement confirming informed consent obtained from study participants.	We have revised the text as suggested（See page 23, line 495-496）	
Report on age and sex for all study participants.	We added some data(See supplement -1)	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	--	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	--	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.	--	
Sample size determination	15 pairs clinical samples for human gene expression microarray; another 43 pairs of lung tissue samples for mRNA expression and protein verification(see page 5, line 111-116)	
Randomisation	Non randomized simultaneous control（see page 7, line 160-162）	
Blinding	Single Blind trial, siNC as control group/ siNC as experimental group（see page7, line 160-162 ）	
Inclusion/exclusion criteria	The clinical diagnosis was non-small cell lung cancer （see page 5, line 111-116）	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	All experiments were performed in triplicate（see page 14, line 303）	
Define whether data describe technical or biological replicates	Technical replicates（see page 14, line 303-304）	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Approval number is KY202014 (see page 23, line 497).	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	--	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Specimen samples have been collected from clinical Patients. Patients have signed the informed consent form, whose files kept in the hospital archives. The approval number was also the relevant permission.	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	--	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	There were not excluded in sample or data	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Refer to statistical software operation manual for data analysis（see page 14, line 300-307）	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	There were 109 up-regulated mRNAs with FC ⩾ 4.0 and the P-value ⩽ 0.05.newly created datasets are available.（see supplement -2）	
If data are publicly available, provide accession number in repository or DOI or URL.	human gene expression microarray data are publicly available, DOI: 10.1159/000494482	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	--	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	--	
State whether the code or software is available.	software is available（see page 14, line 300-307）	
If code is publicly available, provide accession number in repository, or DOI or URL.	--	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	--	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	This manuscript followed relevant guidelines and basically conform to the CONSORT 2010 Checklist.（see supplement-CONSORT 2010 Checklist）	

Article information: http://dx.doi.org/10.21037/tcr-20-1132